[Asia Economy Reporter Lee Seon-ae] Celltrion announced on the 28th that it has signed a supply contract for biosimilar antibody drugs (Remsima IV, Truxima, Herzuma, CT-P16) with Celltrion Healthcare. The contract amount is 175.6 billion KRW, which corresponds to 9.19% of the 2021 sales.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
